Achaogen Awarded $20 Million Contract Option by BARDA to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Achaogen Awarded $20 Million Contract Option by BARDA to Support Development of Plazomicin for Multi-Drug Resistant Gram-Negative Infections

SOUTH SAN FRANCISCO, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO ), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has been awarded $20 million for an additional option, Option 3, on its existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of plazomicin. Plazomicin is the Company’s lead product candidate being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

The BARDA contract was originally awarded to Achaogen under BARDA’s Broad Spectrum Antimicrobials program in August 2010. The original contract consisted of a base award as well as three options that, effective today, have all been exercised. With the granting of this last option, the unspent funding currently committed under the contract with BARDA now totals approximately $41 million. The funding from Option 3 is focused on the Phase 3 pivotal clinical trial of plazomicin, the EPIC study, in complicated urinary tract infections (cUTI). Achaogen expects to release top-line results from the EPIC study in the first quarter of 2017, and plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2017.

“We appreciate BARDA’s overall support of the plazomicin program, including this additional financial support for the Phase 3 EPIC study,” said Kenneth Hillan, M.B. Ch.B., Achaogen's Chief Executive Officer. “Multi-drug resistant gram-negative infections continue to be a serious public health threat, especially given the high mortality rates associated with CRE infections.”

In a separate press release, the Company announced today that it has entered into an agreement to sell shares of its common stock and warrants to purchase shares of common stock for aggregate gross proceeds of approximately $25 million in a private placement to a syndicate of new investors. In addition to this equity financing, the Company plans to draw $10 million in additional debt under its existing loan agreement with Solar Capital Ltd.

About the EPIC Study EPIC ( E valuating p lazomicin i n c UTI) is a multi-national, randomized, controlled, double-blind clinical trial in patients with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP), which is expected to create a substantial opportunity for plazomicin to address unmet medical needs arising from multi-drug resistant (MDR) infections. EPIC is expected to serve as a single pivotal trial supporting a New Drug Application (NDA) for plazomicin in the United States.

About Achaogen Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with Federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201000046C. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com .

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Achaogen’s expectations regarding (i) the timing of enrollment and the success of Achaogen’s ongoing Phase 3 EPIC trial, (ii) whether the Phase 3 EPIC trial will serve as a single pivotal trial supporting an NDA for plazomicin, (iii) the timing for announcing topline results from Achaogen’s Phase 3 EPIC trial and submission of an NDA to the U.S. Food and Drug Administration, (iv) Achaogen’s plans to draw an additional term loan from Solar Capital and (v) the potential for Achaogen’s Phase 3 EPIC trial to create a substantial opportunity for plazomicin to address unmet medical needs arising from MDR infections. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Achaogen's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; specific risks related to the ongoing Phase 3 EPIC trial and Phase 3 CARE trial, including the lack of a prior clinical trial in patients with CRE infections and challenges in enrolling an adequate number of patients with rare infections; the risk of failure to successfully validate, develop and obtain regulatory clearance or approval for the in vitro diagnostic (IVD) assay for plazomicin; the risks and uncertainties of the regulatory approval process; the risks and uncertainties of commercialization and gaining market acceptance; the risk that bacteria may evolve resistance to plazomicin; risks and uncertainties as to Achaogen's ability to raise additional capital to support the development of plazomicin and its other programs; uncertainties regarding the availability of adequate third-party coverage and reimbursement for newly approved products; Achaogen's reliance on third parties to conduct certain preclinical studies and all of its clinical trials; Achaogen's reliance on third-party contract manufacturing organizations to manufacture and supply its product candidates and certain raw materials used in the production thereof; Achaogen's dependence on its President and Chief Executive Officer; risks and uncertainties related to the acceptance of government funding for certain of Achaogen's programs, including the risk that BARDA could terminate Achaogen's contract for the funding of the plazomicin development program; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Achaogen's patents or proprietary rights; and the risk that Achaogen's proprietary rights may be insufficient to protect its technologies and product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Achaogen's business in general, see Achaogen's current and future reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, and its Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor Contact: Hans Vitzthum 212.915.2568 hans@lifesciadvisors.com Media Contact: Denise Powell 510.703.9491 denise@redhousecomms.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 573

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 100

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Secretariat's Legacy Bottled: Bourbon Honors Belmont Win

Updated Category News Views 28

A Toast to Racing History When you think about groundbreaking victories, Secretariat's name is right up there. Now, they’re bottling that history into bourbon. It's not just any day you get a drink inspired by a 31-length victory. Thoroughbred fans and whiskey lovers, listen up because Thirty-One Lengths Bourbon is bringing Secretariat back into the spotlight....

Continue Reading
China Automotive Systems Achieves Record Revenue in 2024

Updated Category News Views 202

Record Revenue Growth at China Automotive Systems China Automotive Systems, Inc. (NASDAQ: CAAS) has reported a remarkable increase in its revenue for the fiscal year 2024, achieving an all-time high of $650.9 million. This represents a significant 12.9% increase from the previous year's revenue of $576.4 million, demonstrating the company's strength in the competitive...

Continue Reading
Future of Energy Storage: A Market Growth Journey Ahead

Updated Category News Views 271

Understanding the Energy Storage Market Potential The global energy storage sector is on the brink of significant growth, projected to escalate from a value of USD 58.9 billion in 2024 to an astonishing USD 204.8 billion by 2033. This remarkable trajectory represents an impressive compound annual growth rate (CAGR) of 14.8%. As the world leans more heavily towards...

Continue Reading
Celebrated Legal Innovators: Reuben Raucher & Blum Shine Bright

Updated Category News Views 116

Reuben Raucher & Blum Earn Legal Visionary Recognition Boutique law firm Reuben Raucher & Blum (RRB), based in Los Angeles, has recently gained significant recognition for its exceptional legal expertise. Partners Tim Reuben and Stephanie Blum have been celebrated as Legal Visionaries in Business of Law magazine. This award acknowledges their remarkable leadership and...

Continue Reading
Baker Hughes Welcomes Ahmed Moghal as New CFO to Drive Growth

Updated Category News Views 294

Baker Hughes Announces New CFO Appointment HOUSTON and LONDON — Baker Hughes Company (NASDAQ: BKR) has officially appointed Ahmed Moghal as the new Chief Financial Officer. Moghal, who has been instrumental in the organization’s financial strategies as the CFO of Industrial & Energy Technology (IET), steps into this pivotal role immediately. His vast experience within...

Continue Reading